N2U0.F Adlai Nortye Ltd.

Healthcare Biotechnology Frankfurt Exchange
13.16 EUR
Close of Nov 12, 2026
0.9100 15.00
Market cap
EUR 773M
P/E
-
P/B
4.04x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is N2U0.F undervalued?

Graham number

The Graham number of Adlai Nortye Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Adlai Nortye Ltd. fundamental analysis

No fundamental analysis for Adlai Nortye Ltd. yet.

Adlai Nortye Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Adlai Nortye Ltd.

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a…

Full company profile